This MSP-1 hybrid antigen, together with a suitable adjuvant, is designed to produce a vaccine that will induce protective antibody responses to polymorphic MSP-1 Block 2 sequences, replicating the network of responses found among immune and semi-immune adults in malaria endemic areas. This evidence concerns the gene ATAD1 and malaria.